Hikma launches sodium acetate injection

Hikma has launched sodium acetate injection in 40 mEq per 20 mL vials in the United States. 

The product was approved with a Competitive Generic Therapy designation from the Food and Drug Administration and is therefore eligible for 180 days of CGT exclusivity. To help address the shortage of this critical product, which is currently impacting hospitals and patients across the United States, Hikma said it will be prioritizing the supply of the 20 mL vials. 

Hikma also will launch sodium acetate injection, in 100 mEq per 50 l and 200 mEq per 100 mL vials at a future date.

[Read more: Hikma intros Kloxxado]

Sodium acetate injection is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It also is used as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Sodium Acetate Injection had a market value of roughly $26 million in the 12 months ending May 2024, per IQVIA.

[Read more: Hikma intros Kloxxado]